[go: up one dir, main page]

CL2018000357A1 - Polipéptidos mrka, anticuerpos y usos los mismos - Google Patents

Polipéptidos mrka, anticuerpos y usos los mismos

Info

Publication number
CL2018000357A1
CL2018000357A1 CL2018000357A CL2018000357A CL2018000357A1 CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1 CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A CL2018000357 A CL 2018000357A CL 2018000357 A1 CL2018000357 A1 CL 2018000357A1
Authority
CL
Chile
Prior art keywords
klebsiella
antibodies
mrka
fragments
same
Prior art date
Application number
CL2018000357A
Other languages
English (en)
Inventor
Qun Wang
Saravanan RAJAN
Chew-Shun Chang
Thompson Jenny Heidbrink
Hung-Yu Lin
Charles Kendall Stover
Meghan Pennini
William Dall'acqua
Partha S Chowdhury
Xiaodong Xiao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of CL2018000357A1 publication Critical patent/CL2018000357A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0266Klebsiella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE DIVULGACIÓN PROPORCIONA PROTEÍNAS DE UNIÓN A MRKA, P.EJ., ANTICUERPOS O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS QUE SE UNEN A MRKA E INDUCEN LA DESTRUCCIÓN OPSONOFAGOCÍTICA DE KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE). LA PRESENTE DIVULGACIÓN TAMBIÉN PROPORCIONA MÉTODOS DE REDUCCIÓN DE KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE) O TRATAMIENTO O PREVENCIÓN DE INFECCIÓN POR KLEBSIELLA (P. EJ., KLEBSIELLA PNEUMONIAE) EN UN SUJETO, QUE COMPRENDEN ADMINISTRAR PROTEÍNAS DE UNIÓN A MRKA, P. EJ., ANTICUERPOS O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, POLIPÉPTIDOS MRKA, FRAGMENTOS INMUNÓGENOS DE LOS MISMOS, O POLINUCLEÓTIDOS QUE CODIFICAN MRKA O FRAGMENTOS INMUNÓGENOS DE LOS MISMOS AL SUJETO.</p>
CL2018000357A 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos CL2018000357A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US201562238828P 2015-10-08 2015-10-08

Publications (1)

Publication Number Publication Date
CL2018000357A1 true CL2018000357A1 (es) 2018-07-20

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000357A CL2018000357A1 (es) 2015-08-24 2018-02-08 Polipéptidos mrka, anticuerpos y usos los mismos

Country Status (16)

Country Link
US (2) US20170073397A1 (es)
EP (1) EP3341004A4 (es)
JP (1) JP2018527924A (es)
KR (1) KR20180042300A (es)
CN (1) CN107921086A (es)
AU (1) AU2016313653A1 (es)
BR (1) BR112018003252A2 (es)
CA (1) CA2995387A1 (es)
CL (1) CL2018000357A1 (es)
CO (1) CO2018001985A2 (es)
HK (1) HK1252350A1 (es)
IL (1) IL257434A (es)
MX (1) MX2018001964A (es)
RU (1) RU2018107056A (es)
TW (1) TW201718626A (es)
WO (1) WO2017035154A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Also Published As

Publication number Publication date
HK1252350A1 (zh) 2019-05-24
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
CN107921086A (zh) 2018-04-17
MX2018001964A (es) 2018-06-19
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
BR112018003252A2 (pt) 2018-09-25
KR20180042300A (ko) 2018-04-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
CL2018000357A1 (es) Polipéptidos mrka, anticuerpos y usos los mismos
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2018000042A1 (es) Anticuerpos de unión a tau
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
CL2018000043A1 (es) Anticuerpos de unión a tau
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
NZ723858A (en) Anti-human ox40l antibodies, uses &amp; methods
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
IL261140A (en) Anti-tnfalpha-antibodies and functional fragments thereof
CL2017000912A1 (es) Anticuerpos que se unen a ccr6 y sus usos
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso